| DC67135 |
Lipid B37 |
Lipid B37 (B37) is an ionizable amino lipid, which can be used to form lipid nanoparticles and deliver mRNA. |
|
| DC60705 |
Lipid FO-32
Featured
|
FO-32 is an artificial intelligence-guided designed ionizable lipid for RNA delivery to the muscle, lung and nose. FO-32 LNPs enable potent transfection throughout the whole ferret lung epithelium, from trachea to alveoli. |
|
| DC60706 |
Lipid FO-35
Featured
|
FO-35 is an artificial intelligence-guided designed ionizable lipid for RNA delivery to the muscle, lung and nose. FO-35 LNPs enable potent transfection throughout the whole ferret lung epithelium, from trachea to alveoli. |
|
| DC67161 |
MPEG-2000-DPPE Na
Featured
|
|
|
| DC67197 |
m7GpppAmpG ammonium
Featured
|
m7GpppAmpG ammonium is a trinucleotide 5′ cap analog with the capping efficiencies for the obtained RNAs of 90%.
|
|
| DC67211 |
m7GpppAmpG Na salt
Featured
|
m7GpppAmpG Na salt is a trinucleotide 5′ cap analog with the capping efficiencies for the obtained RNAs of 90%. |
.gif)
|
| DC60711 |
CL15F 9-5 |
CL15F 9-5 is a piperidine-based ionizable lipid for mRNA delivery and improves the long-term storage stability of mRNA/LNPs at refrigeration temperature as a liquid formulation. CL15F 9-5 LNPs exhibits significantly stronger antigen-specific cellular responses than mice immunized with SM-102 and ALC-0315 LNPs. |
|
| DC67212 |
Acuitas Lipid III-25
Featured
|
Acuitas Lipid III-25 is an novel ionizable amine lipid used for mRNA delivery from Acuitas Therapeutics patent US 10,166,298 B2. It is an analgous of ALC-0315, showing higher activity than ALC-0315. |
|
| DC67213 |
Acuitas II-10
Featured
|
Acuitas II-10 is an novel ionizable amine lipid used for mRNA delivery from Acuitas Therapeutics patent WO2016176330A1 |
|
| DC67214 |
Acuitas II-12
Featured
|
Acuitas II-12 is an novel ionizable amine lipid used for mRNA delivery from Acuitas Therapeutics patent WO2016176330A1 |
|
| DC67215 |
Acuitas Lipid III-7
Featured
|
Acuitas Lipid III-7 is an novel ionizable amine lipid used for mRNA delivery from Acuitas Therapeutics patent US 10,166,298 B2. |
|
| DC67217 |
Moderna Lipid compound 46
Featured
|
Moderna Lipid compound 46 is an novel ionizable amine lipid used for mRNA delivery from Moderna patent WO2017049245A2 |
|
| DC67218 |
Moderna Lipid compound 182
Featured
|
Moderna Lipid compound 182 is an novel ionizable amine lipid used for mRNA delivery from Moderna patent WO2017049245A2 |
|
| DC67221 |
3'OMe-m7GpppAmpG (ammonium) solution (100mM)
Featured
|
3'OMe-m7GpppAmpG ammonium solution (100mM) is a trinucleotide Cap analogue. 3'OMe-m7GpppAmpG ammonium shows a significant translational efficiency. 3'OMe-m7GpppAmpG ammonium can be used as a potential molecular biology tool in the field of mRNA vaccines and mRNA transfection, such as protein production, gene therapy and anti-cancer immunization. |
|
